FDA Guidance on CT Mgmt during COVID-19

U.S. Food & Drug Administration Health Care, Pharma Industry, Strategic Planning

FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.

Read the Guidance now